Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity.
antifungal activity
azoles
filamentous fungi
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
19
05
2023
received:
02
02
2023
accepted:
22
05
2023
medline:
6
9
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
We evaluated the activity of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin against 1468 invasive moulds collected worldwide from 2018 to 2021. Most (>92%) of the Aspergillus spp. isolates were wildtype (WT) to amphotericin B, caspofungin and the azoles. Azole-non-wildtype A. fumigatus rates were higher in Europe (9.5%) and North America (9.1%) than Latin America (0.0%; only 12 isolates) and the Asia-Pacific region (5.3%). Amphotericin B and caspofungin were active against azole-non-wildtype A. fumigatus isolates. Posaconazole and amphotericin B were the most active agents against the Mucorales. Among the less common moulds, several expressed a pan-azole-resistant phenotype; many of these species also showed elevated MIC values (MIC, >2 mg/L) for amphotericin B and caspofungin. Although most isolates of Aspergillus spp. remain WT to the azoles, azole resistance is increasing in both North America and Europe. Amphotericin B and caspofungin exhibit potentially useful activity against azole-resistant A. fumigatus.
Substances chimiques
Antifungal Agents
0
Voriconazole
JFU09I87TR
Itraconazole
304NUG5GF4
Amphotericin B
7XU7A7DROE
Caspofungin
F0XDI6ZL63
posaconazole
6TK1G07BHZ
Azoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
854-868Subventions
Organisme : Gilead Sciences
Informations de copyright
© 2023 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd.
Références
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017;3(4):e57. doi:10.3390/jof3040057
Gold J, Revis A, Thomas S, et al. Clinical characteristics, health care utilization, and outcomes among patients in a pilot surveillance system for invasive mold disease-Georgia, United States, 2017-2019. open forum. Infect Dis. 2022;9(7):ofac215.
Ivanov M, Ciric A, Stojkovic D. Emerging Antifungal Targets and Strategies. Int J Mol Sci. 2022;23(5):2756. doi:10.3390/ijms23052756
Lamoth F, Damonti L, Alexander BD. Role of antifungal susceptibility testing in non-aspergillus invasive mold infections. J Clin Microbiol. 2016;54(6):1638-1640. doi:10.1128/JCM.00318-16
Roth RS, Masouridi-Levrat S, Chalandon Y, et al. Invasive mold infections in allogeneic hematopoietic cell transplant recipients in 2020: have we made enough Progress? Open forum Infect Dis. 2022;9(1):ofab596. doi:10.1093/ofid/ofab596
Seidel D, Meissner A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019;45(1):1-21. doi:10.1080/1040841X.2018.1514366
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3
Lamoth F, Kontoyiannis DP. Therapeutic challenges of non-aspergillus invasive mold infections in immunosuppressed patients. Antimicrob Agents Chemother. 2019;63(11):e01244. doi:10.1128/AAC.01244-19
Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326
Tortorano AM, Prigitano A, Esposto MC, et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to fusarium species in Europe. Eur J Clin Microbiol Infect Dis. 2014;33(9):1623-1630. doi:10.1007/s10096-014-2111-1
Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-e38.
Thornton CR. Detection of the'big five'mold killers of humans: aspergillus, fusarium, Lomentospora. Scedosporium and Mucormycetes Adv Appl Microbiol. 2020;110:1-61.
Araujo R, Oliveira M, Amorim A, Sampaio-Maia B. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis. 2015;34(7):1289-1301. doi:10.1007/s10096-015-2374-1
Friedman DZP, Schwartz IS. Emerging fungal infections: new patients, new patterns, and new pathogens. J Fungi (Basel). 2019;5(3):67. doi:10.3390/jof5030067
Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37(3):415-425. doi:10.1086/376634
Batchelor R, Thomas C, Gardiner BJ, et al. When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients. Open Forum Infect Dis. 2021;8(7):ofab113.
Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362-368. doi:10.1093/cid/civ885
Alanio A, Denis B, Hamane S, et al. Azole resistance of aspergillus fumigatus in immunocompromised patients with invasive aspergillosis. Emerg Infect Dis. 2016;22(1):157-158. doi:10.3201/eid2201.150848
Arikan-Akdagli S, Ghannoum M, Meis JF. Antifungal resistance: specific focus on multidrug resistance in Candida auris and secondary azole resistance in aspergillus fumigatus. J. Fungi (Basel). 2018;4(4):129. doi:10.3390/jof4040129
Berkow EL, Nunnally NS, Bandea A, Kuykendall R, Beer K, Lockhart SR. Detection of TR34/L98H CYP51A mutation through passive surveillance for azole-resistant aspergillus fumigatus in the United States from 2015 to 2017. Antimicrob Agents Chemother. 2018;62(5):e02240. doi:10.1128/AAC.02240-17
Borman AM, Fraser M, Palmer MD, et al. MIC distributions and evaluation of fungicidal activity for amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin and 20 species of pathogenic filamentous fungi determined using the CLSI broth microdilution method. J. Fungi (Basel). 2017;3(2):e27. doi:10.3390/jof3020027
Buil JB, Hagen F, Chowdhary A, Verweij PE, Meis JF. Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant aspergillus fumigatus isolates. J Fungi (Basel). 2018;4(3):103. doi:10.3390/jof4030103
Glampedakis E, Cassaing S, Fekkar A, et al. Invasive aspergillosis due to aspergillus section Usti: a multicenter retrospective study. Clin Infect Dis. 2021;72(8):1379-1385. doi:10.1093/cid/ciaa230
Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the horizon: novel fungal treatments in development. Open forum Infect Dis. 2020;7(2):ofaa016. doi:10.1093/ofid/ofaa016
Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia. 2014;178(1-2):1-9.
Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia. 2012;174(4):259-271. doi:10.1007/s11046-012-9551-x
Rychert J, Slechta ES, Barker AP, et al. Multicenter evaluation of the Vitek MS v3.0 system for the identification of filamentous fungi. J Clin Microbiol. 2018;56(2):e01353. doi:10.1128/JCM.01353-17
Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015;82(4):303-313.
Pfaller MA, Rhomberg PR, Wiederhold NP, et al. In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories. Antimicrob Agents Chemother. 2018;62(10):e01230. doi:10.1128/AAC.01230-18
CLSI, M38Ed3. Reference Method for Broth Dilution Antifungal Susceptibilty Testing of Filamentous Fungi. 3rd ed. Clinical and Laboratory Standards Institute; 2018.
CLSI. M61Ed2 Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. 2nd ed. Clinical and Laboratory Standards Institute; 2020.
CLSI, M57S. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. Clinical & Laboratory Standards Institute; 2022.
CLSI, M59Ed3. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. Clinical and Laboratory Standards Institute; 2020. doi:10.18502/CMM.6.2.2696
CLSI, M38M51S. Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. Clinical & Laboratory Standards Institute; 2022. doi:10.14712/18059694.2022.23
Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicentre study of isavuconazole MIC distributions and epidemiological cutoff values for aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother. 2013;57(8):3823-3828. doi:10.1128/AAC.00636-13
Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48(9):3251-3257. doi:10.1128/JCM.00536-10
Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015;59(3):1745-1750. doi:10.1128/AAC.04435-14
Espinel-Ingroff A, Colombo AL, Cordoba S, et al. International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for fusarium species identified by molecular methods for the CLSI broth microdilution method. Antimicrob Agents Chemother. 2016;60(2):1079-1084. doi:10.1128/AAC.02456-15
Castanheira M, Collingsworth TD, Davis AP, Deshpande LM, Pfaller MA. Isavuconazole nonwildtype aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles. Mycoses. 2021: in press;64:1279-1290. doi:10.1111/myc.13267
Badali H, Canete-Gibas C, McCarthy D, et al. Species distribution and antifungal susceptibilities of aspergillus section Fumigati isolates in clinical samples from the United States. J Clin Microbiol. 2022;60(5):e0028022. doi:10.1128/jcm.00280-22
Garbati MA, Alasmari FA, Al-Tannir MA, Tleyjeh IM. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int J Infect Dis. 2012;16(2):e76-e81. doi:10.1016/j.ijid.2011.10.004
Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of scedosporium and pseudallescheria species. Antimicrob Agents Chemother. 2012;56(5):2635-2642. doi:10.1128/AAC.05910-11
Jenks JD, Seidel D, Cornely OA, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope((R)) registry. Mycoses. 2020;63(5):437-442. doi:10.1111/myc.13067
Beer KD, Farnon EC, Jain S, et al. Multidrug-resistant aspergillus fumigatus carrying mutations linked to environmental fungicide exposure-three states, 2010-2017. MMWR Morb Mortal Wkly Rep. 2018;67(38):1064-1067. doi:10.15585/mmwr.mm6738a5
Wiederhold NP, Gil VG, Gutierrez F, et al. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in aspergillus fumigatus isolates in the United States. J Clin Microbiol. 2016;54(1):168-171. doi:10.1128/JCM.02478-15
Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356(14):1481-1483. doi:10.1056/NEJMc061720
Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms in aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother. 2012;56(1):10-16. doi:10.1128/AAC.05088-11
Howard SJ, Pasqualotto AC, Anderson MJ, et al. Major variations in aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses. 2013;56(4):434-441. doi:10.1111/myc.12047
Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55(1):31-37. doi:10.1093/jac/dkh507
Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15(7):1068-1076. doi:10.3201/eid1507.090043
Chowdhary A, Sharma C, Meis JF. Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S436-S444. doi:10.1093/infdis/jix210
Wiederhold NP, Verweij PE. Aspergillus fumigatus and pan-azole resistance: who should be concerned? Curr Opin Infect Dis. 2020;33(4):290-297. doi:10.1097/QCO.0000000000000662
Pfaller MA, Carvalhaes CG, Messer SA, Rhomberg PR, Castanheira M. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. Diagn Microbiol Infect Dis. 2021;101(3):115473. doi:10.1016/j.diagmicrobio.2021.115473
Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2011;49(2):624-629. doi:10.1128/JCM.02120-10
Messer SA, Carvalhaes CG, Castanheira M, Pfaller MA. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY antifungal surveillance program, 2017-2018. Diagn Microbiol Infect Dis. 2020;97(1):115007. doi:10.1016/j.diagmicrobio.2020.115007
Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65(10):2116-2118. doi:10.1093/jac/dkq279
Lelievre L, Groh M, Angebault C, Maherault AC, Didier E, Bougnoux ME. Azole resistant Aspergillus fumigatus: an emerging problem. Med Mal Infect. 2013;43(4):139-145. doi:10.1016/j.medmal.2013.02.010
Schelenz S, Barnes RA, Barton RC, et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis. 2015;15(4):461-474. doi:10.1016/S1473-3099(15)70006-X
Schelenz S, Owens K, Guy R, et al. National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: evidence of sub-optimal practice. J Infect. 2019;79(2):167-173. doi:10.1016/j.jinf.2019.06.009
Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013. Open Forum Infect Dis. 2017;4(1):ofw268. doi:10.1093/ofid/ofw268
van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011;17(10):1846-1854. doi:10.3201/eid1710.110226
Dalyan Cilo B, Al-Hatmi AM, Seyedmousavi S, et al. Emergence of fusarioses in a university hospital in Turkey during a 20-year period. Eur J Clin Microbiol Infect Dis. 2015;34(8):1683-1691. doi:10.1007/s10096-015-2405-y
Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated Mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186(2):289-298. doi:10.1007/s11046-021-00528-2
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated Mucormycosis. India Emerg Infect Dis. 2021;27(9):2349-2359. doi:10.3201/eid2709.210934
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.
Miceli MH, Lee SA. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses. 2011;54(6):e666-e678. doi:10.1111/j.1439-0507.2011.02032.x